Cara Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr '25 Apr 14, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	24	28	40	577	651	754
Market Cap Growth	-	-30.89%	-92.99%	-11.37%	-13.64%	0.26%
Enterprise Value	31	30	-35	400	462	626
Last Close Price	15.96	18.36	26.75	386.64	438.48	544.68
PE Ratio	-	-	-	-	-	89.65
PS Ratio	3.40	3.92	1.93	13.78	28.28	5.58
PB Ratio	-5.30	-6.09	0.71	3.64	2.86	3.03
P/TBV Ratio	-	-	0.71	3.64	2.86	3.03
EV/Sales Ratio	4.33	4.20	-	9.55	20.05	4.64
EV/EBITDA Ratio	-	-	-	-	-	111.96
EV/EBIT Ratio	-	-	-	-	-	116.31
Debt / Equity Ratio	-9.68	-9.68	0.76	0.01	0.02	0.02
Debt / EBITDA Ratio	-	-	-	-	-	0.79
Asset Turnover	0.08	0.08	0.14	0.20	0.09	0.54
Inventory Turnover	19.56	19.56	43.64	39.46	-	-
Quick Ratio	10.67	10.67	4.09	6.39	9.55	9.90
Current Ratio	11.03	11.03	4.54	7.20	9.84	10.55
Return on Equity (ROE)	-270.01%	-270.01%	-109.80%	-44.25%	-37.12%	3.86%
Return on Assets (ROA)	-41.09%	-41.09%	-49.30%	-25.49%	-21.49%	1.33%
Return on Invested Capital (ROIC)	-49.77%	-49.77%	-58.20%	-27.92%	-22.94%	1.51%
Return on Capital Employed (ROCE)	-	-	-	-	-	2.10%
Earnings Yield	-291.26%	-253.31%	-292.78%	-14.81%	-13.58%	1.11%
FCF Yield	-254.66%	-221.48%	-233.34%	-13.65%	-9.23%	-0.77%
Buyback Yield / Dilution	-1.11%	-1.11%	-0.92%	-5.79%	-5.85%	-12.29%

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q